China NT Pharma Group Company Limited provided earnings guidance for the year ending December 31, 2012. The company expects that the group to record a loss for the year ending December 31, 2012. The loss is principally attributable to the Company's business restructuring measures introduced
during the year in order to enhance its competitiveness and to improve cash flow, which involved gradual exiting from its vaccine and pharmaceutical supply chain business and downsizing of its vaccine sales and promotion team. As a result of these business restructuring measures, the Group will report substantially decreased sales revenue and increased charges for doubtful debts, inventories and staff retrenchment particularly in relation to the vaccine business, likely to lead to a loss for the whole year.